Jonathan Lu
About Jonathan Lu
Jonathan Lu serves as the Senior Director of Translational Medicine and Early Clinical Development at SalioGen Therapeutics, where he leads the Cardiopulmonary Program. He has extensive experience in drug development across various medical fields, including cardiopulmonary and rare diseases.
Work at SalioGen Therapeutics
Jonathan Lu serves as the Senior Medical Director for the Cardiopulmonary Program and Clinical Head at SalioGen Therapeutics. He has held this position since 2022, contributing to the company's focus on innovative therapeutics. In 2023, he was promoted to Senior Director of Translational Medicine and Early Clinical Development, further expanding his role in advancing clinical initiatives. His work at SalioGen Therapeutics emphasizes the translation of scientific research into practical medical solutions.
Education and Expertise
Jonathan Lu holds an MD PhD in Pharmacology from Vanderbilt University, where he studied from 1990 to 1998. He also earned a Bachelor of Science in Neuroscience from Brown University between 1986 and 1990. His educational background provides a strong foundation for his extensive experience in drug development, particularly in cardiopulmonary, neuromuscular, and rare diseases. Lu is recognized for his analytical and collaborative approach to medical challenges.
Background
Jonathan Lu has a diverse professional background in both academia and the pharmaceutical industry. He began his medical training with an Internal Medicine Internship and Residency at the University of California, San Diego, from 1998 to 2001. He then completed a Cardiology Fellowship at the same institution from 2003 to 2006, followed by a Clinical Cardiac Electrophysiology Fellowship at UCSF from 2006 to 2008. His academic career includes a position as an Assistant Professor at Columbia University from 2008 to 2015.
Previous Positions in the Pharmaceutical Industry
Before joining SalioGen Therapeutics, Jonathan Lu held several significant roles in the pharmaceutical industry. He was a Medical Director at AstraZeneca from 2015 to 2017 and then at Sarepta Therapeutics from 2017 to 2019. He later served as a Medical Director at Acceleron Pharma from 2019 to 2022. These positions allowed him to gain extensive experience in clinical development and drug research, particularly in early-phase trials.
Achievements in Drug Development
Jonathan Lu has extensive experience in Phase I-III drug development, focusing on cardiopulmonary, neuromuscular, and rare diseases. His work is motivated by the goal of translating scientific discoveries into novel therapeutics that address significant unmet medical needs. His analytical and agile thinking has contributed to advancements in clinical practices and therapeutic strategies within his areas of expertise.